EGFR expression

News alerts, weekly reports and conference planners

Entrez ID:

1956

Related biomarkers:

‹

›

EGFR expression	Lung Non-Small Cell Squamous Cancer	EGFR expression	Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : A1	necitumumab Sensitive: A1 - Approval necitumumab Sensitive : A1
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
EGFR expression	Chordoma	EGFR expression	Chordoma	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2	lapatinib Sensitive: A2 - Guideline lapatinib Sensitive : A2
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR expression	Colorectal Cancer	EGFR expression	Colorectal Cancer	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
EGFR expression	HER2 Positive Breast Cancer	EGFR expression	HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B	ado-trastuzumab emtansine Sensitive: B - Late Trials ado-trastuzumab emtansine Sensitive : B
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR expression	Squamous Cell Carcinoma of Head and Neck	EGFR expression	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: C1 - Off-label cetuximab Sensitive : C1	cetuximab Sensitive: C1 - Off-label cetuximab Sensitive : C1
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
EGFR expression	Solid Tumor	EGFR expression	Solid Tumor	EGFR806-specific CAR T-cell therapy Sensitive: C2 – Inclusion Criteria EGFR806-specific CAR T-cell therapy Sensitive : C2	EGFR806-specific CAR T-cell therapy Sensitive: C2 – Inclusion Criteria EGFR806-specific CAR T-cell therapy Sensitive : C2
EGFR expression	Ovarian Cancer	EGFR expression	Ovarian Cancer	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3	gefitinib Resistant: C3 – Early Trials gefitinib Resistant : C3
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3	PD-L1 inhibitor Resistant: C3 – Early Trials PD-L1 inhibitor Resistant : C3
EGFR expression	Pancreatic Adenocarcinoma	EGFR expression	Pancreatic Adenocarcinoma	trastuzumab + erlotinib Sensitive: C3 – Early Trials trastuzumab + erlotinib Sensitive : C3	trastuzumab + erlotinib Sensitive: C3 – Early Trials trastuzumab + erlotinib Sensitive : C3
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3	osimertinib Sensitive: C3 – Early Trials osimertinib Sensitive : C3
EGFR expression	Lung Non-Squamous Non-Small Cell Cancer	EGFR expression	Lung Non-Squamous Non-Small Cell Cancer	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3	gefitinib Sensitive: C3 – Early Trials gefitinib Sensitive : C3
EGFR expression	Lung Adenocarcinoma	EGFR expression	Lung Adenocarcinoma	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3	anlotinib + APL-502 Sensitive: C3 – Early Trials anlotinib + APL-502 Sensitive : C3
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	cetuximab + afatinib Resistant: C3 – Early Trials cetuximab + afatinib Resistant : C3	cetuximab + afatinib Resistant: C3 – Early Trials cetuximab + afatinib Resistant : C3
EGFR expression	Triple Negative Breast Cancer	EGFR expression	Triple Negative Breast Cancer	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3	lapatinib Sensitive: C3 – Early Trials lapatinib Sensitive : C3
EGFR expression	Nasopharyngeal Carcinoma	EGFR expression	Nasopharyngeal Carcinoma	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3
EGFR expression	Squamous Cell Carcinoma of Head and Neck	EGFR expression	Squamous Cell Carcinoma of Head and Neck	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3	MRG003 Sensitive: C3 – Early Trials MRG003 Sensitive : C3
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	osimertinib + TP-0903 Sensitive: C3 – Early Trials osimertinib + TP-0903 Sensitive : C3	osimertinib + TP-0903 Sensitive: C3 – Early Trials osimertinib + TP-0903 Sensitive : C3
EGFR expression	Lung Adenocarcinoma	EGFR expression	Lung Adenocarcinoma	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4
EGFR expression	Glioblastoma	EGFR expression	Glioblastoma	paclitaxel Sensitive: D – Preclinical paclitaxel Sensitive : D	paclitaxel Sensitive: D – Preclinical paclitaxel Sensitive : D
EGFR expression	Glioblastoma	EGFR expression	Glioblastoma	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D	selumetinib Sensitive: D – Preclinical selumetinib Sensitive : D
EGFR expression	Glioma	EGFR expression	Glioma	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D	gefitinib Sensitive: D – Preclinical gefitinib Sensitive : D
EGFR expression	Squamous Cell Carcinoma of Head and Neck	EGFR expression	Squamous Cell Carcinoma of Head and Neck	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D	vandetanib Sensitive: D – Preclinical vandetanib Sensitive : D
EGFR expression	Pancreatic Cancer	EGFR expression	Pancreatic Cancer	afatinib Sensitive: D – Preclinical afatinib Sensitive : D	afatinib Sensitive: D – Preclinical afatinib Sensitive : D
EGFR expression	Triple Negative Breast Cancer	EGFR expression	Triple Negative Breast Cancer	AFM24 Sensitive: D – Preclinical AFM24 Sensitive : D	AFM24 Sensitive: D – Preclinical AFM24 Sensitive : D
EGFR expression	Squamous Cell Carcinoma of Head and Neck	EGFR expression	Squamous Cell Carcinoma of Head and Neck	cetuximab + CYNK-101 Sensitive: D – Preclinical cetuximab + CYNK-101 Sensitive : D	cetuximab + CYNK-101 Sensitive: D – Preclinical cetuximab + CYNK-101 Sensitive : D

EGFR expression

Associations